Secondary Prevention of Venous Thrombo Embolism (VTE).

Bio2RDF uri

Secondary Prevention of Venous Thrombo Embolism (VTE).

http://bio2rdf.org/clinicaltrials:NCT00329238

Bio2RDF identifier

NCT00329238

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00329238

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00329238

acronym [clinicaltrials_vocabulary:acronym]

RE-MEDY

http://www.w3.org/2001/XMLSchema#string

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

2,867

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

The general aim of this ...... enous Thrombo-embolism.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Secondary Prevention of Venous Thrombo Embolism (VTE).

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00329238 [clinicaltrials_resource:52d4dda706af442d1aa301bc8e6b7888]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:0341b932402f133f1efa07862c1e7f1c]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:73d017c7517592c8add70a4c2a0efb73]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:029d55ca80e5d26d37feb0e6c2b68c92]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:10f6174785bcf0779f228e62643c711b]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:13e28c7fce45506514031c066cc5dbe7]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:1fca79a81b2de119c4c9333e90bdac5c]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:2754b14e572cbafcc4ca8df4cf14afc3]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:2bad7e50fc2efdbbf0840979725393dd]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:40a24f82e7878acbc33eb31267c4c06e]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:8d3112701652d232eb396bbd1302ea6a]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:9ff1b22c908067606159eedcaef078ab]

Composite of Recurrent VTE or VTE Death at 36 Months 36 months [clinicaltrials_resource:bf537eb0abda65db5551f441c3c991f6]

condition [clinicaltrials_vocabulary:condition]

Thromboembolism [clinicaltrials_resource:8aef77b5a8ef234005539d20511c413f]

condition browse [clinicaltrials_vocabulary:condition-browse]

Thromboembolism [clinicaltrials_resource:8aef77b5a8ef234005539d20511c413f]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Thromboembolism [clinicaltrials_resource:8aef77b5a8ef234005539d20511c413f]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00329238 [clinicaltrials_resource:55b72a0e8431a98818509e0826ce5188]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2011-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Warfarin [clinicaltrials_resource:88557718f409fd9bf3678cd0c1d3d21d]

Dabigatran [clinicaltrials_resource:a7911185a96d753811b41a18bd23201a]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Warfarin [clinicaltrials_resource:00fb95037ac6b3e040933a49bc5cbdfa]

Dabigatran [clinicaltrials_resource:18ceb26a7874adfc4bf05183112c667c]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

link [clinicaltrials_vocabulary:link]

[clinicaltrials_resource:33d30e00e9050dbfb5e33b80596229cc]

[clinicaltrials_resource:d0863b6f55890840db29febf851b905f]

location [clinicaltrials_vocabulary:location]

1160.47.01035 Boehringer Ingelheim Investigational Site [clinicaltrials_resource:f896b1cd2e86a245a1391360f326f5e9]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00329238

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase III, Randomised, Multi ...... ion of Venous Thromboembolism.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1.160469970703125e+3

http://www.w3.org/2001/XMLSchema#float

outcome [clinicaltrials_vocabulary:outcome]

Composite of Recurrent VTE or VTE Death at 36 Months [clinicaltrials_resource:NCT00329238/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Boehringer Ingelheim [clinicaltrials_resource:1f5af28df428803ccefd08f103ea82a2]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica [clinicaltrials_resource:d02ae66908a92f6f2113c3f0ff438539]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00329238 [clinicaltrials_resource:2b83e223fd36f3115e63b6e045b3d8f3]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00329238 [clinicaltrials_resource:e07e2fe3a44fdd9c7682a1c66e7f7b9f]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2005-002536-94

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

start date [clinicaltrials_vocabulary:start-date]

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00329238 study design [clinicaltrials_resource:ef4f735ca4bd90276654fafec43692dd]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00329238

verification date [clinicaltrials_vocabulary:verification-date]

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00329238

http://www.w3.org/2001/XMLSchema#string